Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T19:25:41.532Z.
Consensus retrieved: 2026-10-06T09:18:29.010Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:25:41.532Z.
Quote observation: 2026-10-06T19:24:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2a39ca6935a26d8aa5af55aa8ea7db8fcfa7d32011c972ec9cce8dd9481767f6
Forward PE Ratio (N/A) = Dated Quote Price ($3.54) / Consensus Forward EPS ($-2.59)
FORWARD PE RATIO
N/A
BridgeBio Oncology Therapeutics Inc.
Market Cap
$283.24M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| BridgeBio Oncology Therapeutics Inc. (BBOT) | $283.24M | N/A |
| Aurora Cannabis Inc. (ACB)vs › | $283.39M | N/A |
| Standard BioTools Inc. (LAB)vs › | $283.07M | N/A |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.90M | N/A |
| Abeona Therapeutics Inc. (ABEO)vs › | $285.26M | N/A |
| Sagimet Biosciences Inc. (SGMT)vs › | $286.72M | N/A |
| Larimar Therapeutics, Inc. (LRMR)vs › | $291.39M | N/A |
| Indaptus Therapeutics, Inc. (INDP)vs › | $292.16M | N/A |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $271.35M | N/A |
| SAB Biotherapeutics, Inc. (SABS)vs › | $269.32M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $3.54, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-2.60 | $-3.63 – $-1.56 | 7 | n/m |
| 2027-12-31 | $-2.49 | $-2.61 – $-2.35 | 7 | n/m |
| 2028-12-31 | $-2.48 | $-3.42 – $-1.61 | 10 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
